Advanced

The WNT-5a derived peptide, Foxy-5, possesses dual properties that impair progression of Eralpha negative breast cancer.

Ford, Caroline LU ; Ekström, Elin LU ; Howlin, Jillian LU and Andersson, Tommy LU (2009) In Cell Cycle 8(12). p.1838-1842
Abstract
Despite improvements in detection and treatment, breast cancer remains the most common female cancer worldwide, and metastatic associated mortality is a significant public health issue. Patients with tumors negative for estrogen receptor (ERalpha), have a particularly poor prognosis, partly due to their inability to respond to current endocrine treaments. Expression of Wnt-5a has been associated with prolonged recurrence free survivial in clinical material, and Wnt-5a also inhibits migration and invasion of breast cancer cell lines. Loss of Wnt-5a is associated with loss of ERalpha in clinical breast cancer material, and Wnt-5a signaling upregulates ERalpha in ERalpha negative breast cancer cell lines. A Wnt-5a derived hexapeptide, Foxy-5,... (More)
Despite improvements in detection and treatment, breast cancer remains the most common female cancer worldwide, and metastatic associated mortality is a significant public health issue. Patients with tumors negative for estrogen receptor (ERalpha), have a particularly poor prognosis, partly due to their inability to respond to current endocrine treaments. Expression of Wnt-5a has been associated with prolonged recurrence free survivial in clinical material, and Wnt-5a also inhibits migration and invasion of breast cancer cell lines. Loss of Wnt-5a is associated with loss of ERalpha in clinical breast cancer material, and Wnt-5a signaling upregulates ERalpha in ERalpha negative breast cancer cell lines. A Wnt-5a derived hexapeptide, Foxy-5, has been developed and like Wnt-5a, increases adhesion and inhibits migration of breast cancer cells. Furthermore, Foxy-5 significantly reduced liver and lung metastases in a murine ERalpha negative breast cancer model. Foxy-5 also upregulated ERalpha in this in vivo model and most significantly, in vitro rendered cells responsive to the selective estrogen receptor modulator, Tamoxifen. Together these studies suggest that Foxy-5 may be a potential new supplementary treatment for ERalpha negative breast cancer patients, as it addresses two of the most important aspects of cancer related mortality-non response to endocrine therapy and metastasis. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Cell Cycle
volume
8
issue
12
pages
1838 - 1842
publisher
Landes Bioscience
external identifiers
  • wos:000266955000013
  • pmid:19448401
ISSN
1551-4005
language
English
LU publication?
yes
id
f5ae8853-776d-4f5b-a156-760c4dc44fff (old id 1412205)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/19448401?dopt=Abstract
date added to LUP
2009-06-03 16:40:41
date last changed
2016-04-15 19:34:45
@article{f5ae8853-776d-4f5b-a156-760c4dc44fff,
  abstract     = {Despite improvements in detection and treatment, breast cancer remains the most common female cancer worldwide, and metastatic associated mortality is a significant public health issue. Patients with tumors negative for estrogen receptor (ERalpha), have a particularly poor prognosis, partly due to their inability to respond to current endocrine treaments. Expression of Wnt-5a has been associated with prolonged recurrence free survivial in clinical material, and Wnt-5a also inhibits migration and invasion of breast cancer cell lines. Loss of Wnt-5a is associated with loss of ERalpha in clinical breast cancer material, and Wnt-5a signaling upregulates ERalpha in ERalpha negative breast cancer cell lines. A Wnt-5a derived hexapeptide, Foxy-5, has been developed and like Wnt-5a, increases adhesion and inhibits migration of breast cancer cells. Furthermore, Foxy-5 significantly reduced liver and lung metastases in a murine ERalpha negative breast cancer model. Foxy-5 also upregulated ERalpha in this in vivo model and most significantly, in vitro rendered cells responsive to the selective estrogen receptor modulator, Tamoxifen. Together these studies suggest that Foxy-5 may be a potential new supplementary treatment for ERalpha negative breast cancer patients, as it addresses two of the most important aspects of cancer related mortality-non response to endocrine therapy and metastasis.},
  author       = {Ford, Caroline and Ekström, Elin and Howlin, Jillian and Andersson, Tommy},
  issn         = {1551-4005},
  language     = {eng},
  number       = {12},
  pages        = {1838--1842},
  publisher    = {Landes Bioscience},
  series       = {Cell Cycle},
  title        = {The WNT-5a derived peptide, Foxy-5, possesses dual properties that impair progression of Eralpha negative breast cancer.},
  volume       = {8},
  year         = {2009},
}